






































Management of pregnancy in women
with rheumatoid arthritisSummaryheumatoid arthritis (RA) is a common condition
which occurs more frequently in women than  Rheumatoid arthritis (RA) disease activity may
improve during pregnancy but postpartum flares
are common.
 Patients taking disease-modifying antirheumatic
drugs should be counselled about effective
contraception.
 Knowledge about drug safety in pregnancy is
limited but the Therapeutic Goods Administration
categories and online resources are a guide to the
data currently available.
 Begin prepregnancy counselling as early as possible
to allow for cessation of teratogenic medications
and optimisation of RA disease control.
 For unplanned pregnancies, cease teratogenic
medications immediately and refer to a genetic
counsellor and maternalefetal medicine specialist
for risk assessment and advice.Rmen.1 Its prevalence is about 2% in Australia, and
this is predicted to increase to 3% by 2032.2 Therefore, the
need to manage pregnancy in a womanwith RA is not an
uncommon clinical scenario. Clinicians must be aware of
the teratogenicity of certain disease-modifying antirheu-
matic drugs (DMARDs) used to treat RA, and must
ensure that women taking these drugs are using reliable
contraception. Clinicians also have an important role to
play in prepregnancy counselling to facilitate informed
decisionmaking.We,3 and others,4 have identified unmet
information needs among women with RA, including
needs relating to contraception, pregnancy planning,
pregnancy and early parenting. The aim of our review is
to highlight pertinent issues in managing pregnancy in
women with RA.
Effect of RA on fertility and pregnancy
Despite having normal ovarian reserves,5 women with
RA have fewer children than women in a control group,6
and take longer to conceive.7 The reasons for smaller
family size havenot been fully elucidatedbutmay include
personal choice, uncontrolled inflammatory disease,
sexual dysfunction secondary to RA and the effects of
non-steroidal anti-inflammatory drugs on ovulation and
implantation.8 Clinicians should be aware of the possi-
bility of subfertility, discuss this issue with prospective
parents, and refer to reproductive specialists, when
appropriate.
A recent registry-based study reported increased rates of
spontaneous abortion in women with RA, although pre-
vious studies suggested no increased risk.9 Increased
rates of prematurity, pre-eclampsia, caesarean delivery
and infants with a low birthweight have been reported in
women with RA.10-13 A Dutch study found that women
taking prednisolone had higher rates of preterm delivery,
and those with high disease activity were more likely to
have caesarean delivery and infants with a low birth
weight, but patients with well controlled RA had preg-
nancy outcomes comparable with those of the general
population.14
Effect of pregnancy and lactation on RA
It was reported as early as 1938 that RA disease activity
improved in 90% of women during pregnancy,15 and
numerous subsequent studies have reported similar ob-
servations. A more recent prospective study of pregnant
women with RA supports this finding, but suggests that
rates of remission are more modest than traditionally
thought, and that complete remission is uncommon.16 In
this study, 39% of patients had flared by 26 weeksMJA 204 (2) j 1 February 2016postpartum, confirming another long-held observation
that women with RA are at increased risk of flare in the
postpartum period. Women should be educated about
the likelihood of postpartum flares and safe strategies to
manage these events.
Because prolactin, a pituitary hormone integral to
breastfeeding, is proinflammatory in animal models,17
the effect of breastfeeding on postpartum RA activity
has been investigated. Despite two small studies sug-
gesting that breastfeeding was associated with post-
partum flares of RA,18,19 subsequent larger studies have
not confirmed this association.20,21Prepregnancy counselling
Given the teratogenicity of several DMARDs, treating
practitioners have an obligation to ensure that patients
with RA are counselled regularly about the importance of
reliable contraception while taking these agents.22 One
study found that 28% of women taking methotrexate
(MTX) or leflunomide (LEF) used ineffective contracep-
tion.23 Another reported that despite 84% of women
receiving correct contraceptive advice, one-third of
women taking MTX or LEF were not using any
contraception.24
It is estimated that up to 49%of pregnancies in the general
population are unintended.25 If an unplanned pregnancy
occurs in the setting of exposure to teratogenic drugs, the
medications should be ceased immediately and the pa-
tient referred to a genetic counsellor and maternalefetal
medicine specialist for discussion of risk and further
management.
Clinical focusWomen with RA may question their practitioner about
the possibility of RA inheritance. Controlled cohort
studies have showna relative risk ofRAof 1.5e4.5 infirst-
degree relatives.26 Despite thismodest increase in relative
risk, patients can be reassured that the absolute risk of RA
in their offspring remains small.
Good disease control before conception results in the
best chance of lowdisease activity duringpregnancy and
a reduced risk of postpartum flare.16 Teratogenic medi-
cations need to be ceased and the several months it may
take to ensure stability on a new drug regimen should be
taken into account when planning pregnancy. Recom-
mendations about cessation of medications before
conception also extend to men on MTX and LEF
(although there are no reports of teratogenicity in the
children of men on either drug),27,28 and sulfasalazine
(SSZ), which is known to reversibly impede spermato-
genesis and reduce sperm motility and quality.29 A
preconception referral to a maternalefetal medicine
specialist or obstetrician with an interest in high-risk
pregnancy should also be considered.
Safety of drug therapy in pregnancy
Because of ethical concerns, pregnant and lactating
women are specifically excluded frompremarketing drug
trials. Most pregnancy drug safety data are, therefore,
derived from animal studies or postmarketing surveil-
lance, case reports and large registries. In Australia, the
Therapeutic Goods Administration pregnancy classifica-
tion is used to categorise the safety of drugs in preg-
nancy (https://www.tga.gov.au/australian-categorisation-
system-prescribing-medicines-pregnancy). It is not ahierarchical system, ie, it is not implied that a category B
drug is safer than a category C drug. Although the preg-
nancy classification is widely used, in certain situations it is
of limited use to clinicians in determining suitability of
therapy. For example, while hydroxychloroquine (HCQ)
and MTX are both category D drugs, only HCQ is consid-
ered safe in pregnancy, according to Australian practice
guidelines.30
Of the DMARDs in current use, MTX and LEF are con-
traindicated in pregnancy and breastfeeding, and HCQ
and SSZ are compatible with pregnancy.31 Of the bio-
logical agents, tumour necrosis factor (TNF) inhibitors
may be continued until pregnancy is confirmed, with use
in later gestation determined on a case-by-case basis,32
but all other biological agents should be avoided. If TNF
inhibitors are used during pregnancy, live vaccinations
should be avoided in the infant until 6 months of age,
because of the risk of immunosuppression.33
Given the evolving nature of drug safety data, online re-
sources are particularly helpful for clinicians. Mother-
ToBaby (www.mothertobaby.org), a service of the
Organization of Teratology Information Specialists, and
LactMed (http://toxnet.nlm.nih.gov/newtoxnet/lactmed.
htm), run by the United States National Library of Medi-
cine, are two useful and regularly updated websites.
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